Last reviewed · How we verify
lipid emulsion for TPN
Lipid emulsion provides essential fatty acids and calories as a component of total parenteral nutrition (TPN) for patients unable to eat or absorb nutrients orally.
Lipid emulsion provides essential fatty acids and calories as a component of total parenteral nutrition (TPN) for patients unable to eat or absorb nutrients orally. Used for Total parenteral nutrition (TPN) in patients unable to tolerate enteral feeding, Severe malabsorption or short bowel syndrome, Post-operative nutritional support.
At a glance
| Generic name | lipid emulsion for TPN |
|---|---|
| Also known as | SMOFlipid 20% |
| Sponsor | National Taiwan University Hospital |
| Drug class | Nutritional supplement / Parenteral nutrition component |
| Modality | Small molecule |
| Therapeutic area | Nutrition support / Critical care |
| Phase | FDA-approved |
Mechanism of action
Lipid emulsions are oil-in-water emulsions containing triglycerides, phospholipids, and other lipid components that serve as a concentrated caloric source and supply essential fatty acids (linoleic and alpha-linolenic acid) required for cellular function and membrane synthesis. When administered intravenously as part of TPN, they bypass the gastrointestinal tract and provide direct nutritional support to patients with severe malabsorption, critical illness, or post-surgical conditions.
Approved indications
- Total parenteral nutrition (TPN) in patients unable to tolerate enteral feeding
- Severe malabsorption or short bowel syndrome
- Post-operative nutritional support
Common side effects
- Hypertriglyceridemia
- Lipemia
- Phlebitis at infusion site
- Allergic reactions
- Hepatic steatosis with prolonged use
Key clinical trials
- Effect of a Parenteral Emulsion With Omega3 on Neonates With PPHN and CDH (PHASE2)
- A Phase Ⅲ Study of HR19006 Injection in Postsurgical Parenteral Nutrition (PHASE3)
- Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis (PHASE2)
- Targeted Breast Milk Fortification for Very Low Birth Weight Infants in the NICU (NA)
- The Energy Dose Study (PHASE2)
- Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Associated Hepatic Injury
- Compassionate Use of Omegaven in the Treatment of Parenteral Nutrition Induced Hepatic Injury (NA)
- Study Comparing a Soybean Oil-Based With an Olive Oil-Based Lipid Emulsion in ICU Patients Requiring TPN (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- lipid emulsion for TPN CI brief — competitive landscape report
- lipid emulsion for TPN updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI